Anifrolumab Treatment Improves Patient-Reported Quality of Life and Decreases Disease Activity and Corticosteroid Use in Patients with Systemic Lupus Erythematosus: A Qualitative Study in Denmark

Anifrolumab treatment for systemic lupus erythematosus (SLE) patients in Denmark significantly improved patient-reported quality of life and decreased disease activity and corticosteroid use. The study involved qualitative in-depth interviews with 14 patients and electronic medical record data from 16 patients. Common symptoms like fatigue, joint pain, and hair loss improved with treatment. Patients reported enhancements in daily activities, social life, and emotional well-being, although some impacts remained. The findings highlight the treatment's positive effects on both subjective experiences and objective health parameters.